{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T20:22:49Z","timestamp":1794601369296,"version":"4.9.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Chicago Community Trust"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated substantial weight reduction and cardiometabolic benefit in randomized trials; however, prospective implementation evidence from digital care models and female sex community populations remains limited. Here we report outcomes from an observational study of 8,127 women initiating GLP-1RA therapy (99.8% tirzepatide) through a structured digital program incorporating mandatory biochemical monitoring, weekly video-supported follow-up and clinician-guided dose titration in the UK. Mean weight reduction was 16.1\u2009kg (95% confidence interval 15.9 to 16.2;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001), representing 15.5% of baseline weight; 83.1% achieved \u226510% and 22.4% achieved \u226520% weight loss, with consistent responses across age, baseline weight and socioeconomic strata. Among participants with paired biomarker data, mean glycated hemoglobin decreased by 3.3\u2009mmol\u2009mol\n                    <jats:sup>\u2212<\/jats:sup>\n                    <jats:sup>1<\/jats:sup>\n                    (95% confidence interval 3.1 to 3.4;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001), normalizing in 84.5% of those with baseline diabetes-range values and 96.3% with prediabetes, and lipid parameters improved significantly (reductions in total cholesterol of 0.77\u2009mmol\u2009l\n                    <jats:sup>\u2212<\/jats:sup>\n                    <jats:sup>1<\/jats:sup>\n                    , low-density lipoprotein cholesterol of 0.61\u2009mmol\u2009l\n                    <jats:sup>\u2212<\/jats:sup>\n                    <jats:sup>1<\/jats:sup>\n                    and triglycerides of 0.47\u2009mmol\u2009l\n                    <jats:sup>\u2212<\/jats:sup>\n                    <jats:sup>1<\/jats:sup>\n                    ). Retention was 91.4% at 6\u2009months, with no serious treatment-related adverse events. These findings support the feasibility of delivering structured, digitally enabled obesity pharmacotherapy at scale and provide prospective real-world implementation evidence for this care model. Interpretation is limited by the observational design, absence of a comparator group, self-pay population and 6-month follow-up.\n                  <\/jats:p>","DOI":"10.1038\/s41591-026-04687-x","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:29:52Z","timestamp":1792150192000},"page":"4319-4329","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world, digital-first delivery of GLP-1 receptor agonist therapy in women"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8806-6052","authenticated-orcid":false,"given":"John","family":"Deanfield","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0052-5144","authenticated-orcid":false,"given":"Jamie Lai Chun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1756-9530","authenticated-orcid":false,"given":"Michail","family":"Katsoulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Deanfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4811-6865","authenticated-orcid":false,"given":"Raj","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4603-2393","authenticated-orcid":false,"given":"Riyaz","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8984-0602","authenticated-orcid":false,"given":"Rachael","family":"Joy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1174-186X","authenticated-orcid":false,"given":"Matthew","family":"Noble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna H.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"4687_CR1","unstructured":"Obesity and overweight. WHO fact sheet. WHO https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight (2025)."},{"key":"4687_CR2","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","volume":"403","author":"NCD Risk Factor Collaboration (NCD-RisC).","year":"2024","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222\u2009million children, adolescents, and adults. Lancet 403, 1027\u20131050 (2024).","journal-title":"Lancet"},{"key":"4687_CR3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989\u20131002 (2021).","journal-title":"N. Engl. J. Med."},{"key":"4687_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205\u2013216 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4687_CR5","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221\u20132232 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4687_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/oby.23621","volume":"31","author":"I Lingvay","year":"2023","unstructured":"Lingvay, I. et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity 31, 111\u2013122 (2023).","journal-title":"Obesity"},{"key":"4687_CR7","unstructured":"Overweight and obesity management (NG246). NICE https:\/\/www.nice.org.uk\/guidance\/ng246 (2025)."},{"key":"4687_CR8","unstructured":"Tirzepatide for managing overweight and obesity (TA1026). NICE https:\/\/www.nice.org.uk\/guidance\/ta1026 (2024)."},{"key":"4687_CR9","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","volume":"31","author":"Y Xie","year":"2025","unstructured":"Xie, Y. et al. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat. Med. 31, 951\u2013962 (2025).","journal-title":"Nat. Med."},{"key":"4687_CR10","doi-asserted-by":"publisher","first-page":"e2413172","DOI":"10.1001\/jamanetworkopen.2024.13172","volume":"7","author":"D Do","year":"2024","unstructured":"Do, D. et al. GLP-1 receptor agonist discontinuation among patients with obesity and\/or type 2 diabetes. JAMA Netw. Open 7, e2413172 (2024).","journal-title":"JAMA Netw. Open"},{"key":"4687_CR11","doi-asserted-by":"publisher","first-page":"e2433326","DOI":"10.1001\/jamanetworkopen.2024.33326","volume":"7","author":"H Gasoyan","year":"2024","unstructured":"Gasoyan, H. et al. One-year weight reduction with semaglutide or liraglutide in clinical practice. JAMA Netw. Open 7, e2433326 (2024).","journal-title":"JAMA Netw. Open"},{"key":"4687_CR12","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1056\/NEJMp2312816","volume":"390","author":"I Golovaty","year":"2024","unstructured":"Golovaty, I. & Hagan, S. Direct-to-consumer platforms for new anti-obesity medications - Concerns and potential opportunities. N. Engl. J. Med. 390, 677\u2013680 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4687_CR13","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.2337\/dc24-1082","volume":"47","author":"L Ladebo","year":"2024","unstructured":"Ladebo, L. et al. Real-world use of semaglutide for weight management: patient characteristics and dose titration\u2014a Danish cohort study. Diabetes Care 47, 1834\u20131837 (2024).","journal-title":"Diabetes Care"},{"key":"4687_CR14","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod, M. N. et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 389, 1069\u20131084 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4687_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109\u2013121 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4687_CR16","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"Malhotra, A. et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N. Engl. J. Med. 391, 1193\u20131205 (2024).","journal-title":"N. Engl. J. Med."},{"key":"4687_CR17","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome, P. N. et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N. Engl. J. Med. 384, 1113\u20131124 (2021).","journal-title":"N. Engl. J. Med."},{"key":"4687_CR18","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/S0140-6736(24)01356-4","volume":"404","author":"JL Dellgren","year":"2024","unstructured":"Dellgren, J. L. et al. International coverage of GLP-1 receptor agonists: a review and ethical analysis of discordant approaches. Lancet 404, 902\u2013906 (2024).","journal-title":"Lancet"},{"key":"4687_CR19","doi-asserted-by":"publisher","first-page":"e69466","DOI":"10.2196\/69466","volume":"27","author":"H Johnson","year":"2025","unstructured":"Johnson, H. et al. Impact of digital engagement on weight loss outcomes in obesity management among individuals using GLP-1 and dual GLP-1\/GIP receptor agonist therapy: retrospective cohort service evaluation study. J. Med. Internet Res. 27, e69466 (2025).","journal-title":"J. Med. Internet Res."},{"key":"4687_CR20","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding, J. P. H. et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes. Metab. 24, 1553\u20131564 (2022).","journal-title":"Diabetes Obes. Metab."},{"key":"4687_CR21","doi-asserted-by":"publisher","first-page":"e085304","DOI":"10.1136\/bmj-2025-085304","volume":"392","author":"S West","year":"2026","unstructured":"West, S. et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ 392, e085304 (2026).","journal-title":"BMJ"},{"key":"4687_CR22","doi-asserted-by":"publisher","unstructured":"Wong, J. L. C. Analysis code for: Real world, digital-first delivery of GLP-1 receptor agonist therapy in women. Zenodo https:\/\/doi.org\/10.5281\/zenodo.18821943 (2026).","DOI":"10.5281\/zenodo.18821943"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04687-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04687-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04687-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T19:49:20Z","timestamp":1794599360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04687-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["4687"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04687-x","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.D. has received consulting honoraria from Aegerion, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Novo Nordisk, Pfizer, Sanofi and Takeda; research grants from Aegerion, Alzheimer\u2019s Research UK, British Heart Foundation, Colgate, Medical Research Council (UK), MSD, National Institute for Health and Care Research, Pfizer, Public Health England and Roche; and consulting fees from eMed Healthcare UK Ltd. R.T. has received honoraria from Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Edwards, Medtronic, Menarini and Novartis. R.P. has received honoraria, speaker and consulting fees from Novartis, Menarini and Novo Nordisk. R.J. is an employee of SheMed Limited, and M.N. is an employee of eMed Healthcare UK Ltd. eMed Healthcare UK Ltd. and SheMed Limited co-operated the digital program evaluated in this study. D.H.R. has received consulting honoraria from AbbVie, Altimmune, Amgen, AstraZeneca, Biohaven, Boehringer Ingelheim, Calibrate, Carmot Therapeutics (Roche), CinRx, Eli Lilly, eMed, Epitomee, Gila Therapeutics, Ifa Celtic, Novo Nordisk, Pfizer, Regeneron, Rhythm, Scientific Intake, Source Bio, Structure Therapeutics, Tenvie, Wondr Health and Zealand Pharma; and stock options from Calibrate, Epitomee, Scientific Intake and Xeno Bioscience. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}